Abstract
The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue® (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents. (E-mail: Piscagl@med.unibo.it).
Original language | English |
---|---|
Pages (from-to) | 1369-1375 |
Number of pages | 7 |
Journal | Ultrasound in Medicine and Biology |
Volume | 32 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2006 |
Keywords
- Adverse effect
- Contrast agents
- Contrast-enhanced ultrasonography
- Ultrasound
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging